Grant Esposito is a first-chair trial lawyer with decades of experience in complex commercial disputes and class action litigation. He advises clients in key litigation areas including antitrust, mass torts, product liability, health care, environmental, securities and transactional disputes. Grant serves as a trusted advisor and trial lawyer for multinational companies in a variety of sectors in their most challenging and high-profile matters. In particular, he is recognized for providing expert counsel to life sciences and professional services clients in cross-border disputes.
Throughout his career, Grant has secured notable victories in jury and bench trials throughout the U.S., as well as in arbitration proceedings. He has also been recognized as a leading lawyer by numerous legal and industry publications, including Chambers USA, New York Law Journal and Law 360.
Education
- Fordham University School of Law, J.D.
- Cornell University, B.A.
Admissions & Qualifications
- New York
Awards & Recognition
Best Lawyers in America 2012-2023
Chambers USA: New York, Litigation: General Commercial
Law360 MVP: Intellectual Property 2015
The Legal 500 United States, Dispute Resolution: Product Liability, Mass Tort and Class Action - Defense: Consumer Product 2023
The Legal 500 Unites States, Dispute Resolution: Financial Services Litigation
National Law Journal, Litigation Trailblazers 2016
Matters
Representative Matters*
- Bethpage Toxic Tort Litigation. Lead trial counsel in class action and individual cases alleging environmental contamination and toxic torts in excess of $1 billion. Advise client on related regulatory issues.
- SS&C Technologies, Inc. v. Clearwater Analytics. Defend client against claim of misappropriation of trade secrets.
- Mosher v. DaVita Healthcare Partners Represented client in escrow dispute and related matters arising from $4.2 billion acquisition. Settled on favorable terms.
- Amgen Inc., et al. v. Sandoz Inc., et al. Designed statutory construction strategy that defined the “patent dance” contained in the Biologics Price Competition and Innovation Act, which was affirmed by the U.S. Supreme Court.
- United Food and Commercial Workers Unions and Employers Midwest Health Benefits Fund et al. v. Novartis Pharmaceuticals Corp. et al. Secured dismissal of putative antitrust class action challenging patent settlement.
- United States of America et al v. Novartis AG, et al. Secured dismissal of a False Claims Act lawsuit alleging off-label marketing and kickback scheme.
- In re OxyContin Litigation. Trial counsel for Sandoz; prevailed on all patents.
- In re Fletcher International Ltd. Secured dismissals in New York, Boston, and Louisiana for auditor in alleged Ponzi scheme seeking hundreds of millions in damages.
*Aforementioned matters handled at prior firm